RETINALGENIX TECHNOLOGIES - RTGN STOCK NEWS

Welcome to our dedicated page for RETINALGENIX TECHNOLOGIES news (Ticker: RTGN), a resource for investors and traders seeking the latest updates and insights on RETINALGENIX TECHNOLOGIES stock.

RetinalGeniX Technologies Inc. (RTGN) is an innovative ophthalmic research and development company dedicated to advancing the early detection and treatment of ocular diseases. The company focuses on leveraging cutting-edge technology to address systemic diseases like neurodegenerative, cardiovascular, vascular, metabolic, and diabetic conditions through its pioneering DNA/RNA/GPS™ Pharmaco-Genetic Mapping™ software.

RetinalGeniX is at the forefront of developing high-resolution retinal imaging and home monitoring systems that can provide real-time alerts to both physicians and patients. These systems are designed to screen, diagnose, and manage severe eye conditions such as glaucoma, diabetic retinopathy, and macular degeneration, all without the need for pupil dilation.

Recently, RetinalGeniX has made significant strides in remote diagnostic technology, enabling physicians to perform pre-diagnostic assessments of ocular anatomy remotely. This is particularly critical given the global shortage of ophthalmologists and optometrists. As Dr. Jerry Katzman, CEO of RetinalGeniX, emphasizes, early detection through eye screenings can be a game changer in preventing blindness and managing systemic diseases.

The company is also exploring the intersection of genetic markers and high-resolution retinal imaging to aid in the detection and treatment of multiple systemic diseases. They have commenced a study to identify hematology biomarkers that can personalize medical evaluations for patients undergoing treatment for wet macular degeneration, thus potentially reducing costs and improving patient outcomes.

Additionally, RetinalGeniX is developing therapeutic solutions for dry age-related macular degeneration and Alzheimer's syndrome. The company's investigational studies aim to leverage high-resolution retinal imaging and pharmacogenetic mapping to explore new therapies for these chronic diseases.

With a recent patent granted for a device to detect ocular and systemic diseases, RetinalGeniX continues to innovate in affordable, efficient diagnostic technologies. The company's mission is to expand screening capabilities to the masses, thus improving healthcare outcomes globally.

Under the leadership of its experienced team, including interim CFO Virender Ahluwalia, RetinalGeniX is committed to bringing groundbreaking healthcare technologies to market, with the potential to positively impact millions of patients worldwide.

02/22/2024 06:05 AM

News

RetinalGeniX™ Technologies Inc. Granted a Patent for System And Method For Visualization Of Ocular Anatomy

Rhea-AI Summary

RetinalGeniX Technologies Inc. (RTGN) has been granted a patent for a System And Method For Visualization Of Ocular Anatomy by the USPTO. The invention aims to detect ocular and systemic diseases early by visualizing eye anatomy and identifying changes in eye geography. It can help diagnose various conditions like cataracts, retinitis pigmentosa, Alzheimer's, Parkinson's, and other conformational diseases. The Company believes this patent will revolutionize disease detection and diagnosis.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

12.9%

Tags

12/26/2023 12:45 PM

News

RetinalGeniX™ Technologies Inc. Contracts With MEDsan, Inc. to Provide Diagnostic Testing Services for Its Institutional Review Board to Conduct a Study to Personalize Medical Evaluations for Patients Receiving Treatment for Wet Macular Degeneration

Rhea-AI Summary

RetinalGeniX™ Technologies Inc. (RTGN) has contracted MEDsan, Inc. to provide diagnostic testing services for a study on personalized medical evaluations for patients with wet macular degeneration. The company has also started planning pharmaceutical clinical studies for treating dry Age-Related Macular Degeneration (AMD) and Alzheimer’s/dementia complex studies. Additionally, RetinalGeniX has filed two provisional patents related to these studies and formed an institutional review board to launch a 390-patient clinical study intended to validate the relative suitability of anti-VEGF ocular injection treatments for patient candidates with wet AMD. The company is also developing a high-resolution retinal home and remote monitoring system intended to offer 24/7 real-time alerts to both physicians and patients without requiring dilation of the pupil. The technology aims to prevent blindness through early detection and treatment of ocular diseases and detect initial physiological changes indicating possible future systemic diseases.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

12/21/2023 05:50 AM

News

RetinalGeniX Technologies Inc. Appoints Anatoly Dritschilo, M.D. to the Company’s Medical Advisory Board

Rhea-AI Summary

RetinalGeniX Technologies Inc. (OTCQB: RTGN) announced the addition of Anatoly Dritschilo, M.D. to its Medical Advisory Board. Dr. Dritschilo, a renowned educator and translational scientist, will support the company's development of High-Resolution Retinal Imaging and Pharmaco-Genetic Mapping™ technologies. The company is also progressing in conducting pharmaceutical clinical studies for treating dry Age-Related Macular Degeneration (AMD) and developing plans for a future study of Alzheimer's/Dementia complex. RetinalGeniX has filed two provisional patents related to these studies and formed an institutional review board to launch a 390-patient clinical study intended to validate the relative suitability of anti-VEGF ocular injection treatments for patient candidates with wet AMD.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

12/04/2023 02:45 PM

News

RetinalGeniX Technologies Inc. Appoints Dessy Boneva, MD, FACS to the Board of Directors

Rhea-AI Summary

RetinalGeniX Technologies Inc. (RTGN) announced the addition of Dr. Dessislava Boneva to its Board of Directors. Dr. Boneva, an experienced surgeon, brings over 20 years of experience to the company. RetinalGeniX focuses on developing High-Resolution Retinal Imaging and Pharmaco-Genetic Mapping™ technologies.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

12/01/2023 12:32 PM

News

RetinalGeniX Technologies Inc. Announces Hiring of Interim CFO

Rhea-AI Summary

RetinalGeniX Technologies Inc. (RTGN) has hired Virender Ahluwalia as Interim Chief Financial Officer. The company focuses on developing High-Resolution Retinal Imaging and Pharmaco-Genetic Mapping™ technologies to prevent blindness through early detection and treatment of ocular diseases. Mr. Ahluwalia brings over 15 years of finance and operations experience and is expected to contribute to the company's growth. RetinalGeniX is conducting pharmaceutical clinical studies for treating dry Age-Related Macular Degeneration (AMD) and Alzheimer's/Dementia complex, and has filed provisional patents related to these studies.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

11/28/2023 04:01 PM

News

RetinalGeniX Technologies Inc. Appoints Stephen Tannenbaum to the Company's Business Advisory Board

Rhea-AI Summary

RetinalGeniX™ Technologies, Inc. (RTGN) announced the addition of Stephen Tannenbaum to the Business Advisory Board. Tannenbaum, a seasoned professional in capital markets, will provide strategic business advice, consult on potential mergers and acquisitions, and the development of channels to acquire additional capital for the Company. This move is expected to further strengthen RetinalGeniX as it pursues its mission to revolutionize healthcare technology.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

11/09/2023 12:58 PM

News

RetinalGeniX™ Technologies Inc. Announces the Submission of Two Provisional Patent Applications For Investigational Therapeutic Drugs

Rhea-AI Summary

RetinalGeniX™ Technologies Inc. (OTCQB:RTGN) announced the submission of two provisional patent applications for investigational therapeutic drug candidates RTG-2023 and RTG-2024. RTG-2023 targets dry age-related macular degeneration (AMD) and RTG-2024 is intended for the treatment of dementia, specifically Alzheimer’s syndrome. The company's novel approach includes high-resolution retinal imaging and pharmacogenetic mapping to be combined with the promise of these investigational drugs.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

11/08/2023 05:45 AM

News

RetinalGeniX Contracts With Avania CRO to Provide Guidance for Interactions With FDA on Development of Two Drug Therapies and the RetinalCam™ Image Visualization Device

Rhea-AI Summary

RetinalGeniX™ Technologies Inc. (RTGN) has partnered with Avania CRO to guide its FDA interactions for the development of RTG-2023 for dry age-related macular degeneration and RTG-2024 for Alzheimer’s syndrome dementia, along with the RetinalCam™ image visualization device. Avania is a unique Clinical Research Organization with expertise in ophthalmology, aligning closely with RetinalGeniX’s development plan.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

10/30/2023 02:51 PM

News

RetinalGeniX IRB Approved to Conduct Study to Personalize Medical Evaluations for Patients Receiving Treatment for Wet Macular Degeneration

Rhea-AI Summary

RetinalGeniX Technologies Inc. has announced the launch of an Institutional Review Board for research on its DNA/GPS program. The study aims to identify hematology biomarkers that may help personalize medical evaluations for patients undergoing treatments for wet macular degeneration. The company's goal is to determine if a patient with active exudative AMD will respond better to intravitreal aflibercept versus intravitreal bevacizumab. The study has the potential to reduce costs and improve the safety and efficacy of patient candidate selection for ocular injections.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

09/18/2023 05:59 AM

News

RetinalGeniX Technologies Inc. Focuses on Prevention of Blindness and Early Detection of Multiple Systemic Diseases

Rhea-AI Summary

RetinalGeniX Technologies Inc. releases video webinar on retinal screening medical device technology, combining genetic markers and high-resolution retinal imaging in disease treatment.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

FAQ

What is the market cap of RETINALGENIX TECHNOLOGIES (RTGN)?

The market cap of RETINALGENIX TECHNOLOGIES (RTGN) is approximately 62.5M.

What does RetinalGeniX Technologies specialize in?

RetinalGeniX Technologies specializes in developing high-resolution retinal imaging and pharmaco-genetic mapping technologies for the early detection and treatment of ocular and systemic diseases.

How does RetinalGeniX's technology help prevent blindness?

The company's high-resolution retinal home monitoring system offers real-time alerts for early diagnosis and treatment of severe eye conditions, thereby helping to prevent blindness.

What recent advancements has RetinalGeniX made?

RetinalGeniX has advanced remote diagnostic technology and commenced a study to identify biomarkers for personalized treatment of wet macular degeneration, among other innovations.

Who is leading RetinalGeniX Technologies?

The company is led by Dr. Jerry Katzman, CEO, and Virender Ahluwalia, interim CFO, among other experienced professionals.

What is the DNA/RNA/GPS™ Pharmaco-Genetic Mapping™ software?

This innovative software aids in drug development by providing bio-marker information from DNA and RNA test kits, helping in the early detection of ocular and systemic diseases.

What are the company's key therapeutic focuses?

RetinalGeniX is focusing on developing treatments for dry age-related macular degeneration (AMD) and Alzheimer's syndrome.

How does RetinalGeniX plan to expand its screening capabilities?

The company aims to develop cost-effective, high-resolution retinal mass screening devices that do not require pupil dilation, making widespread screening feasible.

What is the significance of the recent patent granted to RetinalGeniX?

The patent covers an affordable and effective device and method for detecting ocular and systemic diseases, enhancing the company's diagnostic capabilities.

How can physicians benefit from RetinalGeniX's remote diagnostic technology?

Physicians can remotely perform pre-diagnostic assessments of ocular anatomy, enabling timely and efficient patient management, especially important given the shortage of eye care specialists.

What impact could RetinalGeniX's technologies have on global healthcare?

RetinalGeniX's innovative technologies have the potential to provide early detection and treatment options for a wide range of conditions, significantly improving global healthcare outcomes.